Inclusion Criteria:

- Histologic proof of a solid tumor that is now unresectable, not amenable to any other
standard therapies, or patient refuses standard therapy

- Metastatic adenocarcinoma of the pancreas amenable to biopsies (cohort II MTD
only)

- Absolute neutrophil count (ANC) >= 1,500/μL

- Platelets >= 100,000/μL

- Total bilirubin =< upper limit of normal (ULN)

- Aspartate aminotransferase (AST) =< 3 times upper limit of normal (ULN)

- Creatinine =< 1.5 times ULN

- Hemoglobin >= 9.0 g/dL

- International Normalized Ratio (INR) within normal limits (for patients treated at
the MTD)

- Ability to provide informed consent

- Willingness to return to Mayo Clinic for follow up

- Life expectancy >= 12 weeks

- Willingness to provide the biologic specimens as required by the protocol

- Negative serum pregnancy test done =< 7 days prior to registration

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

- Able to swallow or have medication administered through a G-tube and absorb the
medication

- Participant agrees to use an acceptable form of contraception; acceptable forms of
contraception:

- Latex condom (always used with spermicide)

- Diaphragm (always used with spermicide)

- Cervical cap (always used with spermicide)

Acceptable forms of secondary contraceptions, when used along with a barrier method:

- Hormonal contraception methods, including pills, patches, rings, or injections except
progestin-only containing pills (i.e. "Mini-pill")

- Tubal ligation

- Partner's vasectomy

- Intrauterine device (IUD) (non-progesterone T)

- Vaginal sponge (containing spermicide)

- 100% commitment to abstinence

Unacceptable forms of contraception for women of childbearing potential:

- Oral contraception containing progestins only

- IUD progesterone T

- Female condom

- Natural family planning (rhythm method) or breastfeeding

- Fertility awareness

- Withdrawal

- Cervical shield

- Willing to abstain from smoking

- Willing to complete a daily pill diary

Exclusion Criteria:

- Known standard therapy for the patient's disease that is potentially curative or
definitely capable of extending life expectancy

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Any of the following prior therapies:

- Chemotherapy =< 4 weeks prior to registration

- Mitomycin C/nitrosoureas =< 6 weeks prior to registration

- Immunotherapy =< 4 weeks prior to registration

- Biologic therapy =< 4 weeks prior to registration

- Radiation therapy =< 4 weeks prior to registration

- Radiation to > 25% of bone marrow

- Failure to fully recover from acute, reversible effects of prior therapy regardless
of interval since last treatment

- New York Heart Association classification III or IV

- Seizure disorder

- Central nervous system (CNS) metastases if not stable for at least 2-3 months based
on imaging, clinical assessment, and use of steroids, or seizure disorder

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception until 12 months after last study drug dose

- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
considered investigational (utilized for a non-Food and Drug Administration
[FDA]-approved indication and in the context of a research investigation)

- Current therapy with a CYP3A4 inhibitor or inducer

- Immunocompromised patients (other than that related to the use of corticosteroids)
including patients receiving highly active antiretroviral therapy (HAART) treatment

- Receiving any other investigational agent which would be considered as a treatment
for the primary neoplasm

- Active other malignancy, excepting non-melanotic skin cancer or carcinoma-in-situ of
the cervix; if there is a history of prior malignancy, they must not be receiving
other specific treatment (other than hormonal therapy) for their cancer

- History of myocardial infarction =< 6 months, or congestive heart failure requiring
use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

- Abnormalities of the cornea based on history (e.g., dry eye syndrome, Sjogren's
syndrome), congenital abnormality (e.g., Fuch's dystrophy), abnormal slit-lamp
examination using a vital dye (e.g., fluorescein, Bengal Rose), and/or an abnormal
corneal sensitivity test (Schirmer test or similar tear production test)

- More than 2 prior chemotherapy regimens for the current metastatic malignancy; full
dose chemotherapy used in conjunction with concurrent radiation therapy will be
included as prior therapy; Note: prior hormonal therapy (e.g. leuprolide, aromatase
inhibitors, tamoxifen) will be allowed and not included as a prior chemotherapy

- Previous therapy with a hedgehog inhibitor